Business
Moberg Pharma and Karo Healthcare enter into an exclusive license agreement for MOB-015/Terclara in Europe, expanding access and growth potential
Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®.
About this update from Moberg Pharma Ab
STOCKHOLM, Nov. 5, 2025 /PRNewswire/ -- Moberg Pharma AB (publ) has entered into an exclusive licensing agreement with Karo Healthcare AB regarding the commercialization of MOB-015 (Terclara®) in Europe. The agreement comprises 19 European markets, enabling a coordinated launch across all key EU markets under the leading global antifungal brand Lamisil®. The agreement covers 19 European markets, representing a total population of approximately 500 million people including all major EU countries and the United Kingdom ("Big 5") as well as the eleven countries where Terclara® is already approved but not yet launched. This provides Moberg Pharma the opportunity for a coordinated launch in all key European markets. Karo Healthcare will be responsible for marketing, distribution and sales throughout Europe. Financial terms are not disclosed, but the agreement includes royalties and compensation for delivered products. "We are very pleased to enter this partnership with Karo Healthcare, which has a strong commercial presence across Europe. Launching MOB-015/Terclara® under the well-known Lamisil® brand gives us an exceptional opportunity to establish the product as the market leader also beyond Sweden and Norway," says Anna Ljung, CEO of Moberg Pharma. "Moberg Pharma has developed a unique and clinically well-documented product. Being able to launch MOB-015/Terclara® under the Lamisil® brand is a perfect combination of scientific innovation and commercial strength that gives us a unique position in the market," says Christoffer Lorenzen, CEO of Karo. The Lamisil® brand Terbinafine, originally developed and launched by Novartis under the Lamisil® brand, has long been considered the gold standard treatment for skin and foot fungal infections such as athlete's foot and nail fungus. Lamisil® is present in more than 60 markets worldwide and has become synonymous with its active ingredient, terbinafine, while consistently standing at the forefront of antifungal research and innovation. MOB-015/Terclara®, developed by Moberg Pharma, represents the next generation of terbinafine therapy – a new topical formulation. Oral treatment of nail fungus is associated with risks such as interactions with other medications and liver damage, which are avoided with topical treatment. Previous attempts at topi...